FLT3 Inhibitor Doubles Overall Survival in Acute Myeloid Leukemia
Incorporating quizartinib into standard treatment for newly diagnosed acute myeloid leukemia (AML) followed by maintenance therapy with the investigational FLT3 inhibitor improved survival for patients with internal-tandem-duplication (ITD) mutations of FLT3, a placebo-controlled randomized trial showed. In the phase III study of over 500 patients undergoing standard induction and consolidation therapy, median overall survival (OS) […]